AUA 2022 update on important clinical trials in advanced prostate cancer, role of PSMA-PET imaging, treatment advances in hormone sensitive prostate cancer, treatment advances in castration-resistant prostate cancer.
bladder cancer, metastatic urothelial carcinoma, EV-302 trial, KEYNOTE-A39 study, enfortumab vedotin, pembrolizumab, enfortumab vedotin plus pembrolizumab, CheckMate 901 study, nivolumab plus gemcitabine/cisplatin, nivolumab, gemcitabine, antibody-drug…
Guru Sonpavde and Matt Galsky delve into the CheckMate 901 study and its implications for advanced bladder cancer treatment. Dr. Sonpavde outlines the study’s design,…
Zach Klaassen and Rob Svatek explore the potential of cretostimogene, a novel medication for non-muscle invasive bladder cancer. Dr. Svatek describes cretostimogene as an oncolytic…
Andrea Miyahira hosts a discussion with Veda Giri, Ayesha Shafi, and Claire Fletcher, members of the PCF Women in Science Forum Organizing Committee. The forum…
Andrea Miyahira talks with Louise Emmett who shares her unconventional journey into nuclear medicine, sparked by a contrarian spirit and a suggestion against pursuing the…
Zach Klaassen engages with Colin Pritchard in a detailed discussion about genomic testing in prostate cancer. They emphasize the importance of genomic testing, particularly in…
Alicia Morgans interviews Neeraj Agarwal about the CONTACT-02 trial, a phase III study that explores the combination of cabozantinib and atezolizumab in patients with metastatic…
Zach Klaassen and Aaron Berger explore the evolving landscape of non-metastatic castration-resistant prostate cancer (CRPC). Dr. Berger highlights the decreasing frequency of non-metastatic CRPC in…
Daniel George and Stephen Freedland delve into the EMBARK study, a trial on Enzalutamide for high-risk non-metastatic biochemical recurrence of prostate cancer. They explore the…
Shilpa Gupta discusses the challenges and progress of the MAIN-CAV study examining the combination of treatments for urothelial cancer in the U.S., impacted by a…
